A Phase 2 interventional study of Epirubicine, Oxaliplatin, Capecitabine, Panitumumab in KRAS Wild Type and Resectable Type II Gastric Adenocarcinoma, sponsored by Arbeitsgemeinschaft medikamentoese Tumortherapie. Terminated at 6 sites in Austria. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2013-06-04.
Sponsored by Arbeitsgemeinschaft medikamentoese Tumortherapie · Phase 2, Interventional, and Treatment
This is an open label, multicenter, single-arm phase II trial with primary eqirubicine-oxaliplatin-capecitabine chemotherapy and concurrent Pmab in patients with resectable, histologically proven gastric or esophageal cancer.
2,004 studies on the registry are indexed under Adenocarcinoma; 375 are open to participants now.
This study's planned enrollment of 43 is close to the median of 45 across 1,553 interventional studies indexed under Adenocarcinoma.
Browse Adenocarcinoma studies →Arbeitsgemeinschaft medikamentoese Tumortherapie is the lead sponsor of 43 studies on the registry; 6 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
3 cycles(repeated q21d) Epirubicine 50mg/m² i.v. d1 Oxaliplatin 100mg/m² i.v. d1 Capecitabine 500mg/m² bid d1-d21 Panitumumab 9mg/kg i.v. d1
Drug: Epirubicine, Oxaliplatin, Capecitabine, Panitumumab
3 cycles (repeated q 21d) Epirubicine 50mg/m² i.v. d1 Oxaliplatin 100mg/m² i.v. d1 Panitumumab 9mg/kg i.v. d1 Capecitabine 500mg/m² bid d1-21
Efficacy
Proportion of patients with T0 ant T1 disease after neoadjuvant combined chemoimmunotherapy
Safety
Proportion of patients with grade 4 diarrhea
Histopathological response
rate of complete pathological response
overall survival after one year
Progression free survival after one year
Proportion of patients completing 3 treatment cycles
Safety
NCI CTCAE v.3
This study is terminated, as verified in Jun 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Arbeitsgemeinschaft medikamentoese Tumortherapie